Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;70(1):7-10.
doi: 10.1007/s00011-020-01413-2. Epub 2020 Oct 20.

Inflammasome formation in the lungs of patients with fatal COVID-19

Affiliations

Inflammasome formation in the lungs of patients with fatal COVID-19

Stefano Toldo et al. Inflamm Res. 2021 Jan.

Abstract

Objective: The orf8b protein of the coronavirus SARS-CoV, analogous to SARS-CoV-2, triggers the NLRP3 inflammasome in macrophages in vitro. Deregulated inflammasome-mediated release of interleukin-1 family cytokines is important in hyper-inflammatory syndromes, like happens in SARS-CoV-2-mediated cytokine release syndrome. We propose that an intense inflammasome formation characterizes the lungs of patients with fatal COVID-19 disease due to pneumonia and acute respiratory distress syndrome (ARDS).

Methods: Samples from four patients with confirmed COVID-19 pneumonia who had been hospitalized at the Hospital of the University of Trieste (Italy) and died of ARDS and four lung samples from a historical repository from subjects who had died of cardiopulmonary arrest and had not been placed on mechanical ventilation and without evidence of pulmonary infection at postmortem examination were collected. Pathology samples had been fixed in formalin 10% at time of collection and subsequently embedded in paraffin. We conducted staining for ASC (Apoptosis-associated Speck-like protein containing a Caspase recruitment domain), NLRP3 (NACHT, LRR, and PYD domains-containing protein 3), and cleaved caspase-1.

Results: Intense expression of the inflammasome was detected, mainly in leukocytes, within the lungs of all patients with fatal COVID-19 in the areas of lung injury. The number of ASC inflammasome specks per high power fields was significantly higher in the lungs of patients with fatal COVID-19 as compared with the lungs of control subjects (52 ± 22 vs 6 ± 3, P = 0.0064).

Conclusions: These findings identify the presence of NLRP3 inflammasome aggregates in the lungs of fatal COVID-19 pneumonia thus providing the potential molecular link between viral infection and cytokine release syndrome.

Keywords: COVID-19; Cytokine release syndrome; IL-1; NLRP3 inflammasome; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Dr. Toldo reports grants from Olatec, grants from Kiniksa during the conduct of the study. Dr. Bonaventura reports a travel award grant from Kiniksa, outside the submitted work. Dr. Abbate reports grants and personal fees from Olatec, grants from Novartis, grants and personal fees from Kiniksa, grants from Regeneron, during the conduct of the study. In addition, Dr. Abbate has a patent on a Cryopyrin inhibitor issued. All other authors report no conflicts relevant to this work.

Figures

Fig. 1
Fig. 1
Inflammasome in the lungs of patients with fatal COVID-19 infection. Representative images of immunofluorescence from pathology specimens of patients with fatal COVID-19 pneumonia (panels a, c, and e) or subjects who died of cardiopulmonary arrest without evidence of pulmonary infection (panels b, d and f). Staining for inflammasome structures is identified in red in panels A-B, C-D and E–F for ASC (Apoptosis-associated Speck-like protein containing a Caspase recruitment domain), NLRP3 (NACHT, LRR, and PYD domains-containing protein 3), and caspase-1, respectively. Panel g illustrates the quantification of the presence of the inflammasome, expressed as ASC specks per high-power fields, showing a significantly higher number of inflammasomes in COVID-19 patients versus controls. Data expressed as mean and standard deviation. P value generated using 2-tails T test for unpaired samples

References

    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Ronco C, Lavie CJ, et al. Weathering the cytokine storm in COVID-19: therapeutic implications. Cardiorenal Med. 2020;10:277–287. doi: 10.1159/000509483. - DOI - PMC - PubMed
    1. Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5:101. doi: 10.1038/s41420-019-0181-7. - DOI - PMC - PubMed
    1. Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020;11:1518. doi: 10.3389/fimmu.2020.01518. - DOI - PMC - PubMed
    1. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126:1260–1280. doi: 10.1161/CIRCRESAHA.120.315937. - DOI - PMC - PubMed

MeSH terms